

EQA round: BM1/26 - Bone Markers

Deadline: 10.4.2026

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(435) 25-hydroxyvitamin D	[nmol/L]				28							26	19	73
Sample A		67,1	20	30	28							26	19	73
(1) Abbott		59,4	6,9	12	7	0	CVPG	56,1	1	25%	42	70,2	7	
(60) Roche		70,3	12	17	12	0	CVPG	67,6	1,7	25%	50,7	84,5	12	
Other					9	0							7	
							4x 12, 1x 73, 3x 162, 1x 998							
Sample B		133	29	22	28							26	24	92
(1) Abbott		129	18	14	7	0	CVPG	119	2,1	25%	89,2	149	7	
(60) Roche		131	25	19	12	0	CVPG	132	2,5	25%	99	165	12	
Other					9	0							7	
							4x 12, 1x 73, 3x 162, 1x 998							
(434) Osteocalcin	[µg/L]				20							19	15	79
Sample A		19,4	1,3	6,7	20							19	17	89
(60) Roche		19,8	1,1	5,4	16	0	CVPG	19,3	0,24	13%	16,7	21,9	16	
Other					4	0							3	
							3x 73, 1x 164							
Sample B		107	9,5	8,8	20							19	15	79
(60) Roche		110	8,6	7,8	16	0	CVPG	105	1,6	13%	91,3	119	16	
Other					4	0							3	
							3x 73, 1x 164							
(433) PINP	[µg/L]				15							15	15	100
Sample A		31,5	2,7	8,6	15							15	15	100
(60) Roche		30,5	1,4	4,5	12	0	CVPG	29,9	0,49	20%	23,9	35,9	12	
Other					3	0							3	
							3x 73							
Sample B		203	15	7,5	15							15	15	100
(60) Roche		198	12	6,1	12	0	CVPG	196	2,4	20%	156	236	12	
Other					3	0							3	
							3x 73							
(436) Parathyrin biointact (PTH 1-84)	[pmol/L]				2							2	2	100
Sample A		3,49	0,37	11	2							2	2	100
Other					2	0							2	
							1x 60, 1x 164							
Sample B		11,2	0,1	0,9	2							2	2	100
Other					2	0							2	
							1x 60, 1x 164							
(431) Parathyrin intact (PTH)	[pmol/L]				27							24	23	96
Sample A		6,74	2,2	33	27							24	23	96
(12) Beckman Coulter		3,6	0,14	3,9	5	0	CVPG	4,1	0,42	23%	3,15	5,05	5	
(60) Roche		6,62	0,56	8,4	12	0	CVPG	6,46	0,26	23%	4,97	7,95	12	
Other					10	1							7	
							4x 1, 1x 29, 1x 73, 3x 162, 1x 179							
Sample B		22,4	7,1	32	27							24	23	96
(12) Beckman Coulter		12	0,48	4	5	0	CVPG	14	1,4	23%	10,7	17,3	5	
(60) Roche		21,8	2	9,2	12	0	CVPG	21,5	0,67	23%	16,5	26,5	12	
Other					10	1							7	
							4x 1, 1x 29, 1x 73, 3x 162, 1x 179							
(432) Collagen telopeptide β-CTX-I	[ng/L]				21							21	20	95
Sample A		294	32	11	21							21	21	100
(60) Roche		303	24	7,8	18	0	CVPG	296	4,6	17%	245	347	18	
Other					3	0							3	
							3x 73							
Sample B		719	96	13	21							21	20	95
(60) Roche		743	72	9,6	18	0	CVPG	751	23	17%	623	879	18	
Other					3	0							3	
							3x 73							